WEEK IN REVIEW

Dazzle Them: How to Create a Memorable Meeting—You can go cookie cutter or you can go creative. Whatever you decide will leave a lasting mark on your company’s reputation. Click here to learn what a connoisseur of the meeting planning world has to say.

Grim News for CMS, for Everyone—PIt doesn’t matter what your take is, what matters is the take-away. This is a wake-up call and orthopedic companies need to take CMS very seriously. Barb Peterson, President of Emerson Consultants, has the prescription. Take once a day and call Barb in the morning. It’s all here.

BioMimetic Therapeutics Files for IPO—Growth factors are the big deal in spine, trauma, periodontal and soft tissue. BioMimetic Therapeutics, Inc., one of the new generation of biomaterials / growth factor companies, has filed to go public. We review an impressive S-1 here.

Charlie Federico, Orthofix’s CEO, Rides Off—There was a melancholy mood at Orthofix last week as its gentleman CEO, Mr. Charles Federico, announced that his final day as CEO would be March 31. A new CEO, Alan Milinazzo, had been recruited five months earlier. He will have some very large shoes to fill. We give a little of the history of this extraordinary CEO here.

News Shorts—We criticize CMS, but NuVasive, ArthroCare and Artimplant post strong sales numbers, a new osteoarthritis treatment is approved in Europe and coming to the U.S., plus Spine Wave eyes Kyphon’s market. For all the news that is orthopedics, click here.

The Picture of Success- Dr. Bart Sachs—Dr. Sachs is Managing Director of the Texas Back Institute Clinical Research Organization, President of SpineMark Clinical Research Organization, and Senior Vice President of SpineMark. Click here to find out what mom, commandos, and revolutionary thinking had to do with his rise to the top.